🇺🇸 FDA
Pipeline program

Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib

2024-HS-022

Phase 2 small_molecule active

Quick answer

Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib for Platinum-sensitive Relapsed Ovarian Cancer is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Platinum-sensitive Relapsed Ovarian Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials